Adalimumab, a monoclonal antibody directed against tumor necrosis factor-α, already approved for psoriasis and other various rheumatological and gastroenterological diseases [103], is the only biologic agent currently available for the treatment of moderate-to-severe HS resistant to antibiotics. This evidence concerns the gene TNF and psoriasis.